Status:
RECRUITING
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Lead Sponsor:
Alumis Inc
Conditions:
Hepatic Impairment
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, a...
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Key Inclusion Criteria for All Participants:
- Body mass index between 18.0 and 40.0 kg/m2
- Key Inclusion Criteria for Participants with Hepatic Impairment:
- Diagnosis of chronic (\> 6 months), stable hepatic impairment with no clinically significant changes within 30 days prior to dosing, as determined by medical history
- Key Exclusion Criteria for All Participants:
- Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 50 mmHg), or resting pulse rate \< 45 or \> 100 bpm. Measurements may be repeated once in order to determine eligibility
- Key Exclusion Criteria for Healthy Volunteer:
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.
- Positive hepatitis panel and/or positive human immunodeficiency virus test.
- Key Exclusion Criteria for Participants with Hepatic Impairment:
- History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.
- History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.
- Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.
- QTcF \> 480 ms for males or \> 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.
Exclusion
Key Trial Info
Start Date :
April 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06952634
Start Date
April 29 2025
End Date
December 1 2025
Last Update
May 1 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Orange County Research Center
Lake Forest, California, United States, 92630
2
Panax Clinical Research
Miami Lakes, Florida, United States, 33104
3
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
4
Alliance for Multispecialty Research
Knoxville, Tennessee, United States, 37920